Parnassus Investments LLC raised its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 9.9% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,133 shares of the company’s stock after acquiring an additional 102 shares during the period. Parnassus Investments LLC’s holdings in Eli Lilly and Company were worth $531,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. Avaii Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 6.2% in the second quarter. Avaii Wealth Management LLC now owns 938 shares of the company’s stock worth $440,000 after purchasing an additional 55 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. lifted its position in shares of Eli Lilly and Company by 54.4% in the second quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 3,401 shares of the company’s stock worth $1,595,000 after purchasing an additional 1,198 shares in the last quarter. Americana Partners LLC lifted its position in shares of Eli Lilly and Company by 7.8% in the second quarter. Americana Partners LLC now owns 9,723 shares of the company’s stock worth $4,560,000 after purchasing an additional 700 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Eli Lilly and Company by 1.7% in the second quarter. Daiwa Securities Group Inc. now owns 86,784 shares of the company’s stock worth $40,700,000 after purchasing an additional 1,458 shares in the last quarter. Finally, Bank of Stockton bought a new stake in shares of Eli Lilly and Company in the second quarter worth $258,000. Institutional investors own 81.38% of the company’s stock.
Insider Buying and Selling
In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of the stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total value of $130,169,600.00. Following the completion of the transaction, the insider now owns 99,768,810 shares of the company’s stock, valued at $60,404,028,326.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CAO Donald A. Zakrowski sold 600 shares of the stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the transaction, the chief accounting officer now owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total value of $130,169,600.00. Following the completion of the transaction, the insider now directly owns 99,768,810 shares of the company’s stock, valued at approximately $60,404,028,326.40. The disclosure for this sale can be found here. Insiders sold 908,246 shares of company stock valued at $21,078,990,577 over the last quarter. 0.13% of the stock is owned by company insiders.
Eli Lilly and Company Trading Down 1.3 %
LLY stock opened at $608.35 on Wednesday. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The company’s 50-day simple moving average is $561.29 and its 200 day simple moving average is $476.24. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $629.97. The company has a market capitalization of $577.50 billion, a PE ratio of 84.61, a price-to-earnings-growth ratio of 2.95 and a beta of 0.33.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. During the same period in the prior year, the company posted $1.25 earnings per share. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 8.2 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the stock. 22nd Century Group reissued a “maintains” rating on shares of Eli Lilly and Company in a research report on Tuesday, June 27th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $375.00 to $500.00 in a report on Tuesday, June 20th. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $640.00 to $673.00 and gave the stock an “overweight” rating in a report on Wednesday, October 11th. Finally, Royal Bank of Canada boosted their target price on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $540.09.
Check Out Our Latest Report on LLY
About Eli Lilly and Company
(Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Featured Stories
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.
